ArticleDiscover oncology2024
Causal relationship between immune cells and acute myeloid leukemia: a two-sample Mendelian randomization study.
Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Apolipoprotein B is considered a potential therapeutic drug target for the treatment of AML.Discover oncology · 2026Article
- Investigation of the expression and potential mechanistic role of BYSL in acute myeloid leukemia.Clinical and experimental medicine · 2026Article
- Mendelian randomization analysis reveals the causal relationship between immune cells and leukemia.Discover oncology · 2025Article
- Identification and validation of plasma protein biomarkers as therapeutic targets in acute myeloid leukemia: an integrative multi-omics study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune cells are crucial in the etiology of acute myeloid leukemia (AML). Given the genetic, epigenetic, and clonal complexities of AML, pinpointing factors linked to immunotherapy presents a formidable challenge. Moreover, investigations into the connection between immune cells and AML are still in their infancy, necessitating further studies to decode the intricate connections involved. MATERIALS AND
methodsBased on Mendelian independent distribution law, Mendelian randomisation (MR) is an analytical method mainly used in epidemiological aetiology inference. This bidirectional two-sample MR study aims to investigate the causal link between immune cell phenotypes and AML. Pooled phenotypic data from 3,757 individuals in a Sardinian cohort, encompassing 731 immune cell phenotypes, were utilized. Aggregate data on AML were sourced from the FinnGen project of the Finnish Biobank. We analyzed the sensitivity of the results and evaluated heterogeneity, employing Cochran's Q test in conjunction with MR-Egger and MR-Presso to assess pleiotropy levels.
results26 distinct immune cell types were identified that potentially linked causally with AML. Furthermore, our analysis indicated a bidirectional causal link between Resting Treg % CD4 Treg, BAFF-R on memory B cells and AML.
conclusionThis investigation delineates the causal link between immune cell phenotypes and the pathogenesis of AML, thereby unveiling potential therapeutic avenues to modulate immune cell functions in AML patients. It aims to discover innovative therapeutic strategies that target immune evasion tactics to reinstate immune responses against leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.